Integrating Advanced 3D Models with Scalability & Predictability to Enhance Translation & Clinical Confidence & Empower Faster Drug Discovery & Development
The FDA Modernization Act 2.0 has triggered a new mindset for pharma, with Roche launching the Institute of Human Biology to create better models, and MSD collaborating with Inventia to bioprint 3D in vitro models to screen for neurodegenerative therapeutic candidates.
It has never been a more exciting time to bet on 3D tissue models as the future of drug development, as more and more complex in vitro models undergo validation. However, the big question of “when can we have the confidence in standalone 3D models, and how to do it at scale?” persists.
Making its timely return to Boston this May, the 9th 3D Tissue Models Summit will enable you and your team to uncover best practices across 23+ real-world applications of complex in vitro models across drug discovery and development. Join us to learn from and meet the ‘front-line’ experts optimizing and leveraging advanced 3D models to confidently empower your own drug development workflows.
A Snapshot of What to Expect in 2024:
Uncover best practice to interrogate renal pathophysiology using 3D ex vivo cell culture with Pfizer to supercharge the target validation process
Discover methodologies to validate the pathobiology of lung organoid and organ-on-a-chip models with Boehringer Ingelheim to better support candidate efficacy studies
Interrogate the big question of model complexity with Merck to uncover how the study question can affect model design and use
Explore optimized strategies to maintain model replicability within intestinal organoids with Regeneron to ensure efficient scaling up in drug discovery endeavours
Understand techniques to employ microfluidic devices across early drug discovery with Alchemab Therapeutics to probe the blood-brain barrier for drug development